Market closedNon-fractional
Humacyte/HUMA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Humacyte
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Ticker
HUMA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Durham, United States
Employees
184
Website
www.humacyte.com
Humacyte Metrics
BasicAdvanced
$971M
Market cap
-
P/E ratio
-$1.01
EPS
1.61
Beta
-
Dividend rate
Price and volume
Market cap
$971M
Beta
1.61
Financial strength
Current ratio
8.371
Quick ratio
8.199
Long term debt to equity
79.378
Total debt to equity
89.771
Interest coverage (TTM)
-15.31%
Management effectiveness
Return on assets (TTM)
-36.66%
Return on equity (TTM)
-195.68%
Valuation
Price to book
37.14
Price to tangible book (TTM)
37.14
Price to free cash flow (TTM)
-10.212
Growth
Earnings per share change (TTM)
257.84%
3-year earnings per share growth (CAGR)
-70.21%
What the Analysts think about Humacyte
Analyst Ratings
Majority rating from 6 analysts.
Humacyte Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$32M
26.69%
Profit margin
0.00%
NaN%
Humacyte Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.22
-$0.25
-$0.24
-$0.29
-
Expected
-$0.22
-$0.25
-$0.24
-$0.23
-$0.24
Surprise
0.15%
-1.32%
-1.98%
28.89%
-
Humacyte News
AllArticlesVideos
Humacyte wins special advanced-therapy designation for ATEV
Invezz·4 weeks ago
Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)
GlobeNewsWire·4 weeks ago
2 Stocks Under $20 Making Outsized Moves
Schaeffers Research·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Humacyte stock?
Humacyte (HUMA) has a market cap of $971M as of July 27, 2024.
What is the P/E ratio for Humacyte stock?
The price to earnings (P/E) ratio for Humacyte (HUMA) stock is 0 as of July 27, 2024.
Does Humacyte stock pay dividends?
No, Humacyte (HUMA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Humacyte dividend payment date?
Humacyte (HUMA) stock does not pay dividends to its shareholders.
What is the beta indicator for Humacyte?
Humacyte (HUMA) has a beta rating of 1.61. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Humacyte stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.